[Brief] Novo's CagriSema Shows 25% Average Weight Loss in Women in Late-Stage Analysis
Analysis published by Novo Nordisk shows its next-generation obesity medicine CagriSema helped women lose about 25% of body weight on average in late-stage research, ahead of previously reported primary-endpoint results. The compound combines a glucagon-like peptide with a long-acting component and forms a key part of the company’s next phase in obesity treatment development.